Lomitapide for the treatment of hypercholesterolemia.

Amanda J Berberich, Robert A Hegele

Expert opinion on pharmacotherapy 2017 Aug

filter terms:

Homozygous familial hypercholesterolemia (HoFH) is a serious rare inherited condition that leads to extremely elevated levels of low density lipoprotein cholesterol (LDL-C), and predisposes affected individuals to high risk of atherosclerotic vascular disease. Traditional therapies are largely ineffective in managing the hypercholesterolemia in these patients; diet and regular LDL-apheresis are the mainstays of management. Lomitapide is an inhibitor of microsomal triglyceride transfer protein (MTP) that blocks the assembly of metabolic precursors of LDL particles. Lomitapide has been approved for use in the HoFH population. Areas covered: This article explores the basic properties of lomitapide, including its pharmacodynamic, pharmacokinetic and metabolic profiles. It also reports the current market status of lomitapide and its close competitors. Trials of lomitapide are also briefly reviewed as well as the safety and tolerability of the drug. Expert opinion: Lomitapide has been recently approved for use in HoFH, a population that has been traditionally very difficult to effectively manage. While lomitapide has some safety concerns, including gastrointestinal symptoms and potential hepatotoxicity, and has yet to prove long term efficacy on hard cardiovascular endpoints, it does represent an attractive treatment option for a small group of patients who, until now, had very limited available effective therapies.

Citation

Amanda J Berberich, Robert A Hegele. Lomitapide for the treatment of hypercholesterolemia. Expert opinion on pharmacotherapy. 2017 Aug;18(12):1261-1268